Study Evaluating Changes In Mammographic Breast Density
Public ClinicalTrials.gov record NCT00774267. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation Of Changes In Mammographic Breast Density Associated With Bazedoxifene Acetate/Conjugated Estrogens, Raloxifene And Placebo In Postmenopausal Women: An Ancillary Study Of Protocol 3115A1-303-WW
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this study is the change in mammographic breast density between baseline and month 24 for each group.
Study identification
- NCT ID
- NCT00774267
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 507 participants
Conditions and interventions
Conditions
Interventions
- BZA 20 mg/CE 0.45 mg Drug
- BZA 20 mg/CE 0.625 mg Drug
- Raloxifene 60 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 75 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2009 (Type not available)
- Primary completion
- Apr 2010 (Actual)
- Completion
- Apr 2010 (Actual)
- Last update posted
- Apr 8, 2014
2009 – 2010
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Fort Myers | Florida | 33916 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32606 | — |
| Pfizer Investigational Site | New Port Richey | Florida | 34652 | — |
| Pfizer Investigational Site | West Palm Beach | Florida | 33409 | — |
| Pfizer Investigational Site | Decatur | Georgia | 30033 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60610 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40536-0293 | — |
| Pfizer Investigational Site | Lousiville | Kentucky | 40291 | — |
| Pfizer Investigational Site | Southfield | Michigan | 48034 | — |
| Pfizer Investigational Site | Chaska | Minnesota | 55318 | — |
| Pfizer Investigational Site | Billings | Montana | 59102 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89146 | — |
| Pfizer Investigational Site | New Brunswick | New Jersey | 08901 | — |
| Pfizer Investigational Site | Rochester | New York | 14642 | — |
| Pfizer Investigational Site | Raleigh | North Carolina | 27609 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45267 | — |
| Pfizer Investigational Site | Wexford | Pennsylvania | 15090 | — |
| Pfizer Investigational Site | Greenville | South Carolina | 29605 | — |
| Pfizer Investigational Site | Dallas | Texas | 75390 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Charlottesville | Virginia | 22908 | — |
| Pfizer Investigational Site | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00774267, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2014 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00774267 live on ClinicalTrials.gov.